ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,887.36
0.24%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Humanigen Inc (HGEN)

  7. Humanigen Inc (HGEN) Noticias

HGEN

Humanigen (HGEN)

Humanigen Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:HGEN
FechaHoraFuenteTítuloSímboloCompañía
08/01/202416:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HGENHumanigen Inc
15/05/202305:36Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HGENHumanigen Inc
25/04/202315:06Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:HGENHumanigen Inc
19/04/202305:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HGENHumanigen Inc
01/02/202312:21Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:HGENHumanigen Inc
21/10/202204:45PR Newswire (US)HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022NASDAQ:HGENHumanigen Inc
19/10/202204:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN)NASDAQ:HGENHumanigen Inc
14/09/202205:15TipRanksH.C. Wainwright Remains a Hold on Humanigen (HGEN)NASDAQ:HGENHumanigen Inc
15/08/202205:16TipRanksHumanigen (HGEN) Gets a Hold from H.C. WainwrightNASDAQ:HGENHumanigen Inc
12/08/202215:00Business WireHumanigen Reports Second Quarter 2022 Financial ResultsNASDAQ:HGENHumanigen Inc
29/07/202217:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:HGENHumanigen Inc
13/07/202211:41TipRanksHumanigen Stock: Why It Crashed and Where It’s HeadedNASDAQ:HGENHumanigen Inc
12/07/202219:30Business WireHumanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-BNASDAQ:HGENHumanigen Inc
06/07/202222:34Business WireHumanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive ProteinNASDAQ:HGENHumanigen Inc
05/07/202217:57TipRanksHumanigen: Topline Data for Covid-19 Treatment Expected in July; What This Could Mean for the StockNASDAQ:HGENHumanigen Inc
01/07/202205:25TipRanksH.C. Wainwright Reiterates Their Buy Rating on Humanigen (HGEN)NASDAQ:HGENHumanigen Inc
30/06/202207:19Business WireNIH/NIAID Locks ACTIV-5/BET-B DatabaseNASDAQ:HGENHumanigen Inc
19/06/202202:20TipRanksH.C. Wainwright Thinks Humanigen’s Stock is Going to RecoverNASDAQ:HGENHumanigen Inc
17/06/202216:11Business WireHumanigen conclut un accord avec PCI Pharma Services dans le cadre des préparatifs de commercialisation au Royaume-UniNASDAQ:HGENHumanigen Inc
17/06/202216:09Business WireHumanigen trifft eine Vereinbarung mit PCI Pharma Services als Teil der Vorbereitungen für die Vermarktung im Vereinigten KönigreichNASDAQ:HGENHumanigen Inc
16/06/202205:30Business WireHumanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United KingdomNASDAQ:HGENHumanigen Inc
03/06/202206:00Business WireHumanigen Announces Participation and Presentation at Multiple Conferences in JuneNASDAQ:HGENHumanigen Inc
24/05/202205:30Business WireHumanigen Announces Participation and Presentation at H.C. Wainwright Global Investment ConferenceNASDAQ:HGENHumanigen Inc
11/05/202219:43TipRanksHumanigen: A ‘Transformative Year’ Awaits, Says AnalystNASDAQ:HGENHumanigen Inc
09/05/202214:25Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:HGENHumanigen Inc
05/05/202215:00Business WireHumanigen Reports First Quarter 2022 Financial ResultsNASDAQ:HGENHumanigen Inc
04/05/202206:00Business WireHumanigen Announces Participation and Presentation at Multiple Conferences in MayNASDAQ:HGENHumanigen Inc
20/04/202207:18Business WireHumanigen kündigt Veröffentlichung an, die von Experten begutachtet wurde und die potenziellen klinischen und wirtschaftlichen Vorteile von Lenzilumab aus Sicht des NHS darlegtNASDAQ:HGENHumanigen Inc
19/04/202217:53Business WireHumanigen annonce une publication évaluée par des pairs, qui démontre les avantages cliniques et économiques potentiels du lenzilumab du point de vue du NHSNASDAQ:HGENHumanigen Inc
19/04/202205:30Business WireHumanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHSNASDAQ:HGENHumanigen Inc
 Showing the most relevant articles for your search:NASDAQ:HGEN

Su Consulta Reciente

USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
NASDAQ
TSLA
Tesla
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AMZN
Amazon.com
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
GOOGL
Alphabet
NASDAQ
MSFT
Microsoft
NASDAQ
AAPL
Apple
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
COIN
SOLUSD
Solana
CCOM
OILBRENT
Brent Oil
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados